Recent

% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. Message Board

  • nusaiba nusaiba Oct 1, 2013 12:49 PM Flag

    Leerink Swann initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $10.

    Leerink Swann initiates coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $10.

    Leerink analyst says, "We believe that ACHN's portfolio could be attractive to potential partners or acquirers. We note that assets in the HCV protease inhibitor and NS5a inhibitor classes available for partnering are relatively scarce, and historical deals have commanded good premiums...We recognize that ACHN's compounds are still early, and safety or efficacy issues could still arise. However, we believe the risks are mitigated to some extent by a portfolio of three distinct compounds, and we see the upside worth taking the risk."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACHN
8.40+0.01(+0.12%)Jul 27 4:00 PMEDT